Confidential Draft

For Immediate Release
For Further Information Contact:
Andrew Fisher at (301) 608-9292
Email: Afisher@unither.com

UNITED THERAPEUTICS GRANTED ADDITIONAL ARGININE SUPPLEMETATION PATENT OVER PRIOR ART

Silver Spring, MD, November 11, 2003: United Therapeutics Corporation (NASDAQ: UTHR) announced today that the United States Patent and Trademark Office issued United States Patent No. 6,646,006, entitled "Enhancement of Vascular Function by Modulation of Endogenous Nitric Oxide Production or Activity," relating to the company's platform of arginine dietary supplement products.

Arginine is one of the body's twenty essential amino acids and is a necessary precursor to the formation of nitric oxide in the body. Nitric oxide produced in the linings of blood vessels is a potent vasodilator -- an agent that can increase the diameter of blood vessels -- thus improving blood flow. Nitric oxide is also important for mediating key processes that promote healthy circulatory function. In situations where nitric oxide production is diminished, arginine supplementation can help augment nitric oxide production. United Therapeutics currently markets the HeartBar® line of arginine dietary supplement products through its wholly owned subsidiary, Unither Pharma, Inc.

"We are pleased to expand upon our existing patent protection for the use of arginine to promote vascular function," said Paul Mahon, United Therapeutics' General Counsel. "This new patent is a product patent covering arginine compositions that promote nitric oxide formation. That the Patent Office issued this patent after consideration of a large number of prior publications makes this an extremely important patent that provides an even stronger foundation to our arginine supplementation therapy business."

"Arginine sales in the United States hit $20 million in 2002, after growing approximately 100% per year for the previous two years," said Martine Rothblatt, Chairman and CEO of United Therapeutics. "At this growth rate, arginine sales could well exceed $100 million annually in 2005, and sales and licensing revenues from United Therapeutics' arginine patent portfolio have the potential to make an important contribution to our bottom line."

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious, and oncological diseases with unique therapeutic products.

In addition to historical information, this press release contains forward-looking statements about expectations regarding the strength of the newly issued arginine patent and United Therapeutics' existing arginine patent estate and the potential effect of arginine sales on United Therapeutics' finances are based on United Therapeutics' beliefs and expectations as to future outcomes. These expectations are subject to risks and uncertainties such as those described in United Therapeutics' periodic reports filed with the Securities and Exchange Commission that may cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in United Therapeutics' periodic reports and documents filed with the Securities and Exchange Commission, including the company's most recent Form 10-K and Form 10-Q. United Therapeutics is providing this information as of November 11, 2003 and undertakes no obligation to publicly update or revise the information contained in this press release whether as a result of new information, future events or any other reason.